The U.S. Food and Drug Administration (FDA) has approved Dysport, a “next generation” acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement of the appearance of moderate to severe glabellar or frown lines between the brows. Dysport, marketed by Medicis Aesthetics, the distributers of Restylane and Perlane, has been used in over two million treatments worldwide in 27 countries. Studies and patient reports have shown that Dysport m...